// App-Quantinova.ai

2001 : TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia

Researchers

Presenter

  • Catherine Lai

Principal Investigators

  • Stephen Reeder

  • Sarah E. Church

  • Carmen Ballesteros-Merino

  • Ibrahim Aldoss

  • Anjali S Advani

  • John E. Godwin

  • Matthew J. Wieduwilt

  • Martha L. Arellano

  • Geoffrey L Uy

  • Farhad Ravandi

  • Matthew C Foster

  • Emmanuel Gyan

  • Patrick J. Stiff

  • Norbert Vey

  • Ashkan Emadi

  • Matteo Giovanni Carrabba

  • Roland B. Walter

  • Peter H. Sayre

  • Kathy Tran

  • Erin Timmeny

  • Michael P. Rettig

  • Patrick Kaminker

  • John Muth

  • Kuo Guo

  • Tung On Yau

  • Peter J.M. Valk

  • Bob Lowenberg

  • Ivana Gojo

  • Martin Bornhuser

  • John F. DiPersio

  • Jan K Davidson-Moncada

  • Sergio Rutella

Medical Centers

  • Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

  • John van Geest Cancer Research Centre,Nottingham Trent University,Nottingham,United Kingdom

  • NanoString Technologies, Inc., Seattle, WA

  • Providence Cancer Center and Earle A. Chiles Research Institute, Portland, OR

  • Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Providence Medical Center, Portland, OR

  • Moores Cancer Center, University of California, San Diego, La Jolla, CA

  • Winship Cancer Institute of Emory University School of Medicine, Atlanta, GA

  • Washington University School of Medicine, St. Louis, MO

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, Chapel Hill, NC

  • Centre Hospitalier Universitaire, Service D'Hemaologie Et Therapie Cellulaire, Tours Cedex, France

  • Loyola University Chicago Stritch School of Medicine, Maywood, IL

  • Service -Hematologie Clinique, Institut Paoli Calmettes, Marseille, France

  • University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC), Baltimore, MD

  • Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy

  • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

  • University of California, San Francisco, San Francisco, CA

  • MacroGenics, Inc., Rockville, MD

  • MacroGenics, Inc., ROCKVILLE, MD

  • Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO.

  • MacroGenics, Inc., ROCKVILLE, MD

  • Erasmus University Medical Center, Rotterdam, Netherlands

  • Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus Dresden, Dresden, Germany.

  • Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO.

  • Centre for Health, Ageing and Understanding Disease (CHAUD), Nottingham Trent University, Nottingham, United Kingdom

Locations

  • United States

  • United Kingdom

  • France

  • Italy

  • Netherlands

  • Germany

Companies

  • MacroGenics, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • Cluster of Differentiation 2AP

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

  • Tumor protein p53

Drug/Treatment

  • Flotetuzumab

  • TP53

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • NCT02152956

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved